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Abstract
Background: Our understanding of the mechanism regulating pancreatic cancer metastatic phenotype is limited.
We analyzed the role of RHOA and PRKCZ in the motility attitude of two subclones of the pancreatic
adenocarcinoma cell line SUIT-2 (S2), with different in vivo metastatic potential in nude mice: S2-m with a low
metastatic potential and highly metastatic S2-CP9 using RHOA and PRKCZ cell-permeable inhibitory peptides.
Methods: Adhesion assays, cell permeable peptides, RHOA activity assay, western blotting
Results: When used in combination cell-permeable inhibitory peptides partially inhibited cell adhesion by about
50% in clone S2-CP9. In clone S2-m, the effect was limited to 15% inhibition. In a wound healing assay, S2-CP9 was
sensitive only to treatment with the combination of both RHOA and PRKCZ inhibitory peptides. Conversely, S2-m
was unable to migrate toward both ends of the wound in basal conditions. Migration of cells through a
membrane with 8 μm pores was completely abolished in both clones by individual treatment with RHOA and
PRKCZ inhibitory peptides.
Conclusion: Herein, we demonstrate a critical role for RHOA and PRKCZ in the regulation of different aspects of
cell motility of pancreatic adenocarcinoma and demonstrate the need to inhibit both pathways to obtain a
functionally relevant effect in most assays. These results indicate that RHOA and PRKCZ, and their downstream
effectors, can represent important pharmacological targets that could potentially control the highly metastatic
attitude of PDAC.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is the most
common type of cancer of the pancreas, accounting for
more than 85% of pancreatic malignancies. PDAC is an
aggressive and devastating disease characterized by rapid
progression and resistance to treatment. With a median
survival of less than 6 months, a diagnosis of pancreatic
adenocarcinoma carries one of the most dismal prog-
noses in all of medicine [1].
A key feature of malignant cells is their capacity to
invade surrounding tissues and metastasize to distant
sites. Little is known about the motile attitude of PDAC
cells and the signalling events controlling their motility.
These include cell spreading and polarization, as well as
generation of focal adhesion, focal contacts, filopodia,
lamellipodia, ruffles, and intercellular junctions. Each of
these events is under the control of specialized and
distinct signaling pathways, which are likely to be
altered in cancer cells [2]. In addition, many of the sig-
naling molecules controlling cell motility are also
involved in the regulation of cell cycle and cell transfor-
mation [3].
The study of cancer cell migration in vitro has been
considered a valid model for cancer cell migration as it
shares several key features as demonstrated by in vivo
models and requires GTPase activity which provides a
positive feedback mechanism [4].
The process of metastasis involves a complex series of
events that include cell transformation and proliferation,
vascular invasion at the primary growth site with asso-
ciated basement membrane degradation, transport
through capillary or lymphatic vessels, attachment of
tumor cells to endothelial or subendothelial structures
at the secondary site, and subsequent growth of a sec-
ondary tumor mass.
Analysis of quantitative parameters of cell motility in
cancer cells may help to identify intracellular signaling
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some of these issues, we studied two subclones of a cell
line derived from a pancreatic adenocarcinoma SUIT-2
(S2) with similar in vitro motility but different in vivo
metastatic potential in nude mice: S2-m, a previously
described motile clone isolated in our laboratory [3],
and S2-CP9, metastatic to the lung upon subcutaneous
implantation [5]. We have previously demonstrated the
specific involvement of the PRKCZ isoenzyme in the
regulation of pancreatic cancer cell motility [3]. The aim
of this study was to extend those findings and under-
stand whether differential regulation of cell motility
occurs in the individual clones, by comparing the effects
on cell motility and in vitro invasion of RHOA and
PRKCZ inhibitory peptides. Instrumental to this are the
capability of synthetic peptides, with sequences identical
to the endogenous PKC pseudosubstrate region, to inhi-
bit the activity of the different PKC isoforms [6] and the
availability of highly selective inhibitory peptides to
block RHOA-dependent signaling in a region-selective
manner [7-9].
Our results suggest a critical and complementary role
of these signaling molecules in the regulation of differ-
ent aspects of cancer cell movement, and underline the
need of combined inhibition of both pathways or a com-
mon effector to interfere with cell migration processes
in the highly metastatic clone.
Materials and methods
Cell lines
S2-m [3] and S2-CP9 [5] subclones of the SUIT-2
PDAC cell line were maintained in RPMI 1640, supple-
mented with heat-inactivated fetal bovine serum (final
concentration 10%) and grown in a humidified 5% CO2
atmosphere at 37°C.
Motility and experimental metastasis assays
Twelve primary tumor samples (Table 1) were dissected
after surgery, plated on 24 well plates for short-term cul-
ture in RPMI 1640 high-glucose, 10% FBS and 50 μg/ml
gentamycin. Motility was evaluated in all samples by time-
lapse microscopy exactly as described for S2-m [3]. Cell
lines analyzed include MCC1 [10], AVC1[11] and SKPC1
[12]. For lung metastasis assay 2 × 10
6 S2-m and S2-CP9
cells were resuspended in 0.2 ml of RPMI and inoculated
subcutaneously in the flank of four week old nu/nu Swiss
mice weighing 18-22 g (Charles River, Milan, Italy). The
animals were visually inspected every two days for 8 weeks
when they were euthanized following the guidelines of the
local animal facility. Lungs were stained with India ink
through the trachea, fixed in Fekete’s solution, and the
number of lung colonization was counted under a dissect-
ing microscope following established protocols [13].
Table 2 summarizes the results obtained.
Evaluation of RHOA activity and PRKCZ expression
S2-m and S2-CP9 cell lines were serum starved for 24
hours, followed by addition of complete medium for 2
hours at 37°C, 5% CO2. Cells were then lysed and
RHOA activity was measured by the RHOA G-LISA
Activation Assay, colorimetric detection versions,
according to the manufacturer’s instructions (Cytoskele-
ton, Inc. distributed by Tebu-Bio, Italy). RHOA activity
was evaluated with was measured with a VICTOR X3
Multilabel Plate Reader (PerkinElmer, Shelton, USA)
with absorbance set at 490 nm. 10 μg of proteins from
the same cell lysates were resolved on SDS-PAGE, elec-
troblotted onto polyvinylidene difluoride membranes
(Millipore Corp., Bedford, MA). Non specific binding on
the membrane was blocked with 3% bovine serum albu-
min (BSA, Sigma-Aldrich) in TBS-T buffer (0.05%
Tween 20 in Tris-buffered saline pH 7.5) for 1 h at RT.
Membrane was incubated with primary antibodies
(1 μg/ml) in TBS-T with 1% BSA overnight at 4°C. The
Table 1 Motility of pancreatic cancer cells
Primary tumors Sex Age Diagnosis Motility (μm/min)
PT-1 M 59 PDAC 0,3
PT-2 M 70 PDAC 1 ± 0,2
PT-3 M 61 PDAC 0,4 ± 0,1
PT-4 M 54 PDAC 0,8 ± 0,2
PT-5 F 66 PDAC 0,8 ± 0,2
PT-6 F 76 PDAC 1,5 ± 0,1
PT-7 F 69 PDAC 0
PT-8 M 68 PDAC 0
PT-9 M 70 ACT 0
PT-10 F 63 IPMT 0
PT-11 F 61 PET 0
PT-12 F 42 PET 0
Cell lines
MCC1 / / MCT-CR 0
AVC1 / / AVC 0,1
SK-PC1 / / PDAC 2 ± 0,3
S2-m / / PDAC 3.3 ± 0.8
S2-CP9 / / PDAC 4 ± 2
PT = Primary Tumor; PDAC: pancreatic ductal adenocarcinoma, ACT: Acinar
Tumor, IPMT: intraductal papillary mucinous tumor, PET: pancreatic endocrine
tumor, MCT-CR: mucinous cystic tumor-carcinoma, AVC: ampulla Vateri cancer.
Data calculated by evaluation of three microscopic fields containing an
average of 10 cells.
Table 2 Number of lung metastases in nude mice from
subcutaneus implant of the subclones S2-CP9 and S2-m
Mice n. S2-CP9 S2-m
13 0
20 0
32 3
41 0 0
51 6 0
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polyclonal IgG), anti-RHOA (26C4 SC-418 Mab), anti-
alpha-actin (rabbit IgG A2066 from Sigma-Aldrich,
Milan, Italy). Blots were washed three times in TBS-T
and then incubated for 1 h at room temperature with
secondary antibody conjugated to horseradish peroxi-
dase: goat anti-mouse IgG (NA931V, 1:3000, HRP-con-
jugated from sheep, GE Healthcare, Milan, Italy) and
anti-rabbit IgG (NA934V 1:20000, HRP-conjugated from
donkey, GE Healthcare) in TBS-T, 1% BSA at RT. Mem-
branes were treated for 30 min at 65°C in 0.5 mM Tris
pH 6.7, 2% SDS, 100 mM b-mercaptoethanol and
washed before probing with additional antisera.
RHOA and PRKCZ cell permeable inhibitory peptides
The PRKCZ inhibitory peptide (synthesized at the Stan-
ford University Protein and Nucleic Acid Facility) was
dissolved immediately before use at a concentration of 1
mM in DMSO. The peptide sequence from the pseudo-
substrate region of human PRKCZ isozyme is SIYRR-
GARRWRKLYRAN (positions 113-129). The P1-RHOA
23-40 peptide was obtained from the Penetratin-1 (P1)
fusion protein expression vector pTm3Hb in which the
oligonucleotide encompassing human RHOA bases 67-
120 (aa 23-40) was inserted between the BamHI and
KpnI cloning sites. Recombinant proteins were
expressed in E. coli BL21(DE3)pLysS Gold and purified
on heparin columns, dialyzed against PBS, and stored at
-80°C. P1-23-40 peptide was synthesized by Sigma-
Genosys. A glycine was inserted between P1 and RHOA
regions to allow greater flexibility of the peptides. The
features and specificity of this tool have been thoroughly
described [8,9,14].
Cell adhesion assay
Adhesion assays were performed. 100 μlo fc e l ls u s p e n -
sion (3 × 10
4 cells/ml) were seeded on 96-well microtiter
plate (Orange laboratories). The day after cells were trea-
ted for 18 hours at 37°C with 50 μM P1-RHOA 23-40
peptide. Subsequently, 50 μMo fP R K C Zp e p t i d ew a s
added and the incubation continued for 2 hours at 37°C.
Wells were then washed with PBS, 1 mM Mg
++,1m M
Ca
++, fixed and stained with Crystal Violet (0.75% Crystal
Violet; 0.25% NaCl; 1.75% Formaldehyde; 50% Ethanol)
for 5 minutes. The plates were then washed twice with
MilliRO water to remove excess dye, air dried, and adher-
ent cells lysed by the addition of 100 μl PBS containing
1% SDS. The plate was analyzed in a Packard Spectra-
Count® Photometric Microplate Reader at 590 nm.
In vitro migration assays
Migration was assessed using transwell inserts with 8
μm pores through a PVP-free polycarbonate membrane
filter (Costar Corp., Cambridge, MA). Peptides was
added in 600 μl of complete RPMI 10 min before the
transwells were transferred to wells, paying attention to
avoid air bubbles. 100 μl of cells suspension (1 × 10
5
cells/ml) were allowed to migrate for 16 h at 37°C in 5%
CO2. Non-migrating cells on the upper surface of the
membrane were removed by scraping using cotton
tipped swabs. Transwells were inserts in a 24 well plate
containing 500 μl of Crystal Violet staining solution for
5 minutes, and then treated as previously described.
In vitro wound-healing assay
The in vitro wound-healing assay utilized was described
by Caveggion et al. [15]. Briefly, cells were cultured in
24 well plates until confluent. Peptides were added
immediately prior to monolayer scratching with the tip
of a pipette in order to wound the monolayer. Photo-
micrographs at 10× objective magnification were taken
after 6 hours thereafter to assess cell migration [16].
Statistical analysis
We performed one-Way ANOVA analyses with Dun-
nett’s multiple comparison test for the adhesion assay. A
p < 0.05 was considered statistically significant.
Results
Characterization of S2-m and S2-CP9 clones
We quantified the motility and metastatic capability in
nude mice of the SUIT-2 subclones S2-m and S2-CP9.
Table 1 describes the values measured in these clones
and in other pancreatic cancer cell lines together with a
series of primary tumor samples.
T h em e t a s t a t i cc a p a b i l i t yt ot h el u n go fS 2 - mw a s
lower (1 mice out of 5, with 3 metastatic nodules) with
respect to S2-CP9 (4 out of 5 mice, with an average of 6
metastatic nodules). Table 2 summarizes the results.
RHOA and PKCZ expression did not differ signifi-
cantly among clones (Figure 1A). RHOA activity also
overlaps among clones (Figure 1B).
Effects of RHOA and PRKCZ inhibitory peptides on
morphology and adhesion
We evaluated the adhesion of the SUIT-2 subclones S2-
m and S2-CP9. The number of adherent cells after 24
hours in the presence of DMSO or P1 peptide, used as
controls, did not differ significantly between S2-m and
S2-CP9. Incubation with 50 μM P1-RHOA 23-40 or 50
μM PRKCZ inhibitory peptides (Figure 2) had no affect
on adhesion of the S2m cell line when utilized in plate
adhesion assays (Figure 3). In contrast, for the S2-CP9
clone, the addition of the individual peptides reduced
cell adhesion by 25%. The combination of both peptides
induced a marginal inhibition of adhesion in S2-m cell
lines, while the inhibition was robust in S2-CP9, where
it reached 50%.
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migration ability
As a result of the different effects of the two peptides
observed in the adhesion assay, we evaluated the moti-
lity and migration features of the two subclones.
Migration ability was measured by wound healing and
transmigration assays. The former measures the ability
of the cell lines to cover a scratch in a tissue culture
plate and is related to the dynamics of cellular move-
ment on a surface. For this purpose, 50 μMR H O Aa n d
50 μM PRKCZ inhibitory peptides were added, alone or
in combination, to confluent monolayer of cells immedi-
ately prior to scratching with a yellow tip. As shown in
Figure 4, 6 hours after wounding, non-stimulated S2-
CP9 reached almost confluence (nearly 60% of the
wound was covered), whereas RHOA and PRKCZ pep-
tide treated cells remain close to time 0, suggesting a
significant reduction of random locomotion. Quantita-
tive analysis, revealed a 90% inhibition of the wound
healing by RHOA and PRKCZ in S2-CP9 cells. The S2-
m clone was far less efficient in covering the wound,
indicating an impairment of random locomotion. Treat-
ment with the peptide was therefore not measurable
(see additional file 1).
We next performed a transmigration assay, as described
in the Materials and Methods, to evaluate the ability of
cells to actively modify their shape to pass through 8
μm pores, mimicking the ability of the cells to overstep
endothelial cell barriers in micro vessels and to pene-
trate the extracellular matrix. Treatment with 50 μM
PRKCZ or 50 μM P1-RHOA 23-40 inhibitory peptides
Figure 1 Expression of RHOA and PRKCZ. Panel A: The level of
expression of RHOA and PRKCZ in S2-m and S2-CP9 subclones of
the SUIT-2 pancreas cancer cell line is overlapping. Actin (ACTB)
served for normalization. Panel B: RHOA activity assay in S2-m and
S2-CP9 clones show that not only expression but also the activity of
RHOA is overlapping in both clones (n = 2).
Figure 2 RHOA and PRKCZ cell permeable inhibitory peptides.
A: Site organization of RHOA and PRKCZ showing the effector
regions of RHOA (aa 23-40, 75-92 and 92-119), and the inhibitory
pseudosubstrate region of PRKCZ (aa 113-129). B: Representation of
the the plasma membrane translocating peptides. The 23-40 RHOA
effector region was fused to Penetratin-1 (left). A myristic acid was
added at the N-terminal of the pseudosubstrate region of PRKCZ
(right).
Figure 3 Role of RHOA and PRKCZ on cell adhesion. Percentage
of the variation of the signal intensity of adherent S2-m and S2-CP9
clones between control and inhibitory peptides-treated cells, with
100% the absorbance found after Crystal Violet staining in the cell
lines without treatment. S2-CP9 appear to respond to the individual
inhibitory peptides and to their combination while S2-m clone
adhesion is unaffected by all the treatments.
Peruta et al. Molecular Cancer 2010, 9:61
http://www.molecular-cancer.com/content/9/1/61
Page 4 of 8either alone or in combination almost completely sup-
pressed the ability of both S2-m and S2-CP9 to migrate
to the bottom surface of the transwell (Figure 5).
Discussion
The invasive and metastatic capability of malignancies is
associated with the acquisition of anomalous motile
behavior by cancer cells, which in turn is dependent on
complex biochemical cellular changes whose nature is
still not clarified. PDAC is a lethal malignancy whose
aggressive behavior depends on several factors, including
a strong and early tendency for invasion and metastasis.
Even small lesions, less than 1 cm, can be associated
with the invasion of both surrounding tissues and lym-
phatic vessels [17]. In order to address the extent to
which the metastatic capability of a cell line is associated
Figure 4 In vitro wound-healing assay uncover a selective role for both RHOA and PRKCZ in S2-CP9. Only the combined effect of 50 μM
RHOA and 50 μM PRKCZ peptides (as indicated on the left) are effective in inhibiting wound healing selectively in S2-CP9 clone. S2m appear
incapable to cover the wound, demonstrating a defect in random movement, therefore the effect of the inhibition of the indicated pathways
can not be evaluated in S2m. Photomicrographs at 10× magnification were taken at the beginning and after 6 hours from the start of treatment
to assess cell migration and were mounted together following appropriate reference marks. One representative of 3 individual experiments.
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t h es a m eP D A Cc e l ll i n e :am o t i l ec l o n ed e r i v e df r o ma
clone with a lower metastatic capability in nude mice
(S2-m) and a second clone (S2-CP9) that is metastatic
to the lung upon subcutaneous implantation. We per-
formed our studies in vitro, and evaluated the sensitivity
of the two clones to selective inhibitors of RHOA and
PRKCZ. The signaling mechanisms involved in the regu-
lation of PDAC cell motility showed that PRKCZ, an
atypical isozyme of the serine-threonine protein kinase
C, plays a critical role in maintaining a high motility
score in motile subclones. These results were obtained
by measuring the effect of specific cell permeable pep-
tides with a sequence corresponding to the pseudosub-
strate inhibitory region [3].
PRKCZ is known to associate with Smurf1 to form a
complex with Cdc42-PAR6 that induces membrane pro-
trusions and mediates the ubiquitin-dependent degrada-
tion of RHOA [18]. PRKCZ was recently shown to act
on IKK kinase. IKK members (IKK epsilon) have been
involved in F actin assembly, which is necessary for
polarized movement in Drosophila [19].
RHOA activity in the cell is primarily related to cytos-
keleton regulation. RHO proteins play a central role in
regulating cell shape, polarity and locomotion through
their effects on actin polymerization, actyomyosin con-
tractility, cell adhesion, and microtubule dynamics [20].
RHOA is a member of the Ras homology family of
small GTPases. These proteins cycle from an active
(GTP-bound) to an inactive (GDP-bound) conformation
by hydrolyzing GTP to GDP. Specific guanine exchange
factors (GEFs) reactivate the GTPases by catalyzing the
replacement of GDP with a new GTP. Other regulatory
factors include GTPase-activating proteins (GAPs),
which deactivate RHOA by enhancing its GTPase acti-
vity (thus converting the protein more rapidly to its
GDP-bound inactive form), and guanine nucleotide dis-
sociation inhibitors (GDIs), which inhibit GAP’sf u n c -
tioning and consequently slow the GTPase activity of
RHOA [21-23].
Recent studies have shown its indirect involvement
(through associated factors) in myosin phosphorylation
and cellular responses to stress, such as the formation
of focal adhesions and actin stress fibers [24]. It has also
been shown to be directly related to myosin chain elon-
gation, actin filament rearrangement, gene expression,
cell-shape determination, and cell proliferation [23,24].
These findings and others have sparked recent research
interest in the potential involvement of RHOA in onco-
genesis. Indeed, over expression of RHOA has been
associated with colon, breast, lung, and testicular germ
cell cancers as well as in head and neck squamous-cell
carcinomas [2]. Different hypotheses regarding RHOA
role in these cancers are being explored. One possibility
is that the GTPase activity of RHOA provides control
for processes necessary for tumorigenesis, such as vesi-
cle transport and cell shape change [2]. Another, not
incompatible hypothesis is that metastasis of cancers
m a yb ea f f e c t e db yR H O Ar o l ei nc e l lm o t i l i t ya n dp r o -
cess formation [18].
Our experiments demonstrate that both RHOA and
PRKCZ are involved in different aspects related to cell
adhesion and motility on a surface or through 8 μm
pores in S2m and S2-CP9 clones. There are some differ-
ences that distinguish the clones: adhesion to plastic
plates is only slightly reduced (by 15%) by the simulta-
neous inhibition of both RHOA and PRKCZ in the
S2-m clone. In the highly metastatic clone, however, the
same phenomenon is inhibited by 50%. Additionally, as
the individual inhibition of RHOA and PRKCZ enzymes
leads to a 25% reduction of adhesion, the 50% inhibition
obtained by their use in combination suggests an addi-
tive effect. These observations imply that distinct, inde-
pendently regulated signaling pathways, which appear to
be partially dependent on RHOA and PRKCZ, regulate
cell adhesion in these clones.
When the capability of random movement was tested by
the wound-healing assay, S2m was unable to migrate
toward both ends of the wound even if its motility over-
lapped that of S2-CP9. In the latter, only the combined
inhibition of RHOA and PRKCZ led to the inhibition of
the wound healing capability, a measure of the dynamic of
cellular movement on a surface, and individual treatment
Figure 5 In vitro migration assays reveal a role for both RHOA
and PKRCZ. Individual and combined inhibition of PKRCZ and
RHOA pathways strongly inhibits the capability of all the clones to
migrate through 8 μm pores. OD values determined by Crystal
Violet staining of the subclones migrated through the membrane of
the Transwell Assay, without and in the presence of the inhibitory
peptides indicated. The values of OD are proportional to the
number of cells present on the lower surface of the transwell
(average values from three individual experiments).
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tive. This indicates that these cells are able to activate an
alternative pathway that maintains this capability when the
function of one of the enzymes is inhibited.
We next studied how both clones behaved in an
experimental setting where migration of the cells occurs
through an 8 μm pore membrane, representing a model
of cell deformability and movement through tissues. In
this case, at variance with the wound healing assay,
spontaneous migration through the pores occurs,
although to a different extent, in both clones and was
almost completely abolished by individual treatment
with RHOA and PRKCZ inhibitory peptides. These
results validate those obtained in the wound healing
assay as they demonstrate that the individual pathways
are present and active in both S2-m and S2-CP9 clones
This result also suggest that the pathways regulating
this phenomenon are either distinct from the ones that
regulate adhesion and polarized locomotion or are more
sensitive to even a partial inhibition of the signaling ori-
ginating by RHOA and PRKCZ. Taken together, all
these assays indicate that S2-CP9 clone appear to have
acquired the capability to better regulate cytoskeleton
dynamics compared to clones that are motile but with a
lower metastatic capacity. They also suggest that the
pathways regulated by RHOA and PRKCZ are con-
nected but capable to independently control specific
aspects of cell motility, as shown by the results obtained
in adhesion and transmigration assay at variance with
that of random locomotion assay.
Protein interaction network analysis reveal interactions
between both RHOA and PRKCZ with CDC42, FADD,
CASP8 and PRKCA. FADD and CASP8 do not appear
to be involved in cellular movement and cytoskeleton
rearrangement through actin reorganization [25,26]. We
have already shown that PRKCA inhibition is unable to
alter cell motility [3].
Together these results highlight the role of CDC42.
CDC42 is a small GTPase of the RHO-subfamily, well
described as regulator of signaling pathways that con-
trols diverse cellular functions including cell morphol-
ogy, migration, endocytosis and cell cycle progression.
The reorganization of actins into podosomes is con-
trolled by CDC42, a GTP-binding protein [27]. CDC42,
as previously described, was found to associate to
PRKCZ [28] and acts together with RHOA in the pro-
cess of depolymerization of actin filaments or microtu-
bules controlling the morphology, motility, and division
of most cell types [29].
T h ec o m m o ni n t e r a c t i o no fb o t hR H O Aa n dP R K C Z
with CDC42 could explain the experimental results
obtained, indicating the resistance to the disruption of
the signal originating by the individual partners in the
wound healing assay in S2-CP9 clone and the
requirement of a combined inhibition of both RHOA
and PRKCZ signaling activity to obtain a full biological
effect.
Our results indicate that metastatic clones acquire
specific capabilities related to cell motility, and that an
approach leading to functional interference must take in
account that multiple pathways need to be inhibited to
reach a functionally relevant effect. In fact, we show that
inhibition of a single target or the evaluation of a
reduced set of cell motility features can lead to underes-
timation or even masking the contribution of a selected
pathway to the biological phenomenon under study.
Our results also suggest RHOA and PRKCZ (and possi-
bly CDC42) represent promising targets for the develop-
ment of drugs that interfere with the development or
progression of the metastatic phenotype and underline
the importance of a detailed dissection of the complexity
of signaling pathways involved in cancer cell movement.
Additional file 1: Quantification of wound coverage assay of the
subclones S2-CP9 and S2-m. the table show the effect of the indicated
peptides on wound healing assay taken at 18 hrs after treatment.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-61-
S1.DOC]
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